Study of Two Add-on Eye drop combinations for reducing eye pressure in Glaucoma patients

TO COMPARE THE THERAPEUTIC EFFICACY OF 0.004 PERCENT TRA VOPROST IN COMBINATION WITH 0.02 PERCENT NETARSUDIL VS 0.004 PERCENT TRA VOPROST IN COMBINATION WITH 0.5 PERCENT TIMOLOL IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/095461

Enrollment

Registered

2025-09-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H401- Open-angle glaucoma

Interventions

Intervention1: Travoprost 0.004% + Netarsudil 0.02% ophthalmic solution: Travoprost 0.004% ophthalmic solution in combination with Netarsudil 0.02% ophthalmic solution, administered as one drop topica

Eligibility

Inclusion criteria

Inclusion criteria: 1Old and new Eligible candidates with bilateral open angle glaucoma diagnosed on GAT, gonioscopy, fundus examination and visual field defects. All the previous anti-glaucoma drugs will be stopped for 3-4 weeks. OCT will be performed on a baseline basis and after 6 months. 2 Age greater than or equal to 18 years 3 Unmedicated IOP greater than 20 mm Hg and less than 36 mm Hg in both eyes despite treatment with Travoprost monotherapy for at least 6 weeks 4On Travoprost as a first line therapy for POAG, but showing insufficient IOP control and visual field deterioration. 5BCV A of 20/200 or better in at least 1 eye. 6Able to comply with general study requireme

Exclusion criteria

Exclusion criteria: 1History of narrow angles or iridocorneal angle closure. 2Congenital glaucoma 3Previous refractive surgery 4Any active ocular inflammation or infection. 5Clinically significant dry eye syndrome that could interfere with IOP measurement or treatmentadherence. 6Central corneal thickness greater than 620 microns 7Known hypersensitivity or contraindications to Netarsudil or latanoprost (or their excipients). 8Other ocular diseases that might interfere with the study 9Use of systemic or ocular medications which can alter IOP within the past 4 weeks. 10Pregnant or lactating women. 11Participation in another clinical trial involving investigational drugs or devices within the past 30 days.

Design outcomes

Primary

Measure	Time frame
To compare the reduction in mean IOP with the use of 0.004 percent Travoprost in combination with 0.02 percent Netarsudil v/s 0.004 percent Travoprost in combination with 0.5 percent timolol in patients with primary open angle glaucoma.Timepoint: Baseline, 1 month, 3 months	—

Secondary

Measure	Time frame
The safety profile of 0.004 percent Travoprost in combination with 0.02 percent Netarsudil v/s 0.004 percent Travoprost in combination with 0.5 percent timolol in patients with primary open angle glaucoma.Timepoint: Baseline, 1 month, 3 months	—

Countries

India

Contacts

Public ContactDr Vinod Sharma

IGMC Shimla

Drsharma.track@gmail.com9805122115

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026